Key Developments: Symmetry Medical Inc (SMA.N)

SMA.N on New York Stock Exchange

9.03USD
1 Aug 2013
Price Change (% chg)

$0.32 (+3.67%)
Prev Close
$8.71
Open
$8.76
Day's High
$9.40
Day's Low
$8.76
Volume
90,531
Avg. Vol
79,380
52-wk High
$12.82
52-wk Low
$7.45

Search Stocks

Latest Key Developments (Source: Significant Developments)

Symmetry Medical Inc Reaffirms FY 2013 Guidance
Thursday, 1 Aug 2013 07:02am EDT 

Symmetry Medical Inc announced that for fiscal 2013, it is reiterating its guidance and expects revenue to be in the range of $400 million to $415 million, GAAP earnings per diluted share to be in the range of $0.14 to $0.24 and adjusted earnings per diluted share to be in the range of $0.40 to $0.50. This includes a negative $0.02 impact of the Medical Device Excise Tax in G&A expense. The as adjusted earnings per diluted share guidance excludes the impact of amortization of intangible assets and debt issuance costs, stock compensation expense, acquisition related costs, facility closure and severance costs and other one-time expenses. These items are expected to negatively impact fiscal 2013 GAAP earnings per diluted share by approximately $0.26. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $408 million and EPS of $0.44 for fiscal 2013.  Full Article

Symmetry Medical Inc Lowers FY 2013 Guidance
Monday, 10 Jun 2013 04:12pm EDT 

Symmetry Medical Inc announced that for fiscal 2013, the Company expects revenue to be in the range of $400 million to $415 million, compared to the previously announced revenue range of $420 million to $440 million, GAAP earnings per diluted share (EPS) to be in the range of $0.11 to $0.21 and as adjusted earnings per diluted share (EPS) to be in the range of $0.40 to $0.50. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $426 million and EPS of $0.63 for fiscal 2013.  Full Article

Symmetry Medical Inc Reaffirms FY 2013 Guidance
Thursday, 2 May 2013 07:01am EDT 

Symmetry Medical Inc announced that for fiscal 2013, it expects revenue to be in the range of $420-$440 million. The Company expects fiscal 2013 GAAP earnings per diluted share to be in the range of $0.35-$0.47 and as adjusted earnings per diluted share (EPS) to be in the range of $0.64-$0.76. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $434 million and EPS of $0.71 for fiscal 2013.  Full Article

Symmetry Medical Inc Issues FY 2013 Guidance; EPS Guidance Below Analysts' Estimates
Thursday, 21 Feb 2013 07:00am EST 

Symmetry Medical Inc announced that for fiscal 2013, it expects revenue to be in the range of $420-$440 million. The Company expects fiscal 2013 GAAP earnings per diluted share to be in the range of $0.35-$0.47 and as adjusted earnings per diluted share (EPS) to be in the range of $0.64-$0.76. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $438 million and EPS of $0.77 for fiscal 2013.  Full Article

Symmetry Medical Inc Raises FY 2012 Revenue Guidance; Lowers FY 2012 EPS Guidance
Thursday, 1 Nov 2012 07:01am EDT 

Symmetry Medical Inc announced that it has narrowed fiscal 2012 guidance to a tighter range, with revenue now expected to be $410 to $415 million, with a corresponding tightening of as adjusted EPS guidance to $0.55 to $0.60. For fiscal 2012, the Company expects revenue to be in the range of $410-$415 million, compared to the previous guidance of $410 million to $425 million, GAAP earnings per diluted share (EPS) to be in the range of $0.26 to $0.31 and as adjusted earnings per diluted share to be in the range of $0.55 to $0.60. This compares to the previous guidance of GAAP EPS in the range of $0.30 to $0.40 and as adjusted EPS in the range of $0.55 to $0.65. The as adjusted* earnings per diluted share guidance excludes the impact of amortization of intangible assets and debt issuance costs, stock compensation expense, acquisition related costs, legal entity restructuring costs, SEC-related legal costs, management transition costs, and facility closure and severance costs. These items are expected to negatively impact full year 2012 GAAP earnings per diluted share by approximately $0.29.  Full Article

Symmetry Medical Inc Announces FDA Clearance of Its FLASH PAK Evolution Valve
Tuesday, 28 Aug 2012 08:30am EDT 

Symmetry Medical Inc announced that it received United States Food and Drug Administration (FDA) 510K clearance for its FLASH PAK Evolution valve. The Evolution valve is the next generation valve for Symmetry's immediate use (flash) sterilization product, FLASH PAK, and is distributed exclusively through Symmetry Surgical. The patent pending stainless steel construction of the new valve is designed for ease of use and simplicity of care.  Full Article

Symmetry Medical Inc. Reaffirms FY 2012 Guidance
Thursday, 2 Aug 2012 07:00am EDT 

Symmetry Medical Inc. announced that based on the second quarter 2012 results, the Company is reiterating its fiscal 2012 revenue and earnings per share guidance. For the full year 2012, the Company expects revenue to be in the range of $410 million to $425 million. The Company expects fiscal 2012 GAAP earnings per diluted share to be in the range of $0.30 to $0.40 and fiscal 2012 as adjusted earnings per diluted share (EPS) to be in the range of $0.55 to $0.65. The as adjusted earnings per diluted share guidance excludes the impact of amortization of intangible assets and debt issuance costs, stock compensation expense, acquisition related costs, legal entity restructuring costs, SEC-related legal costs, management transition costs, and facility closure and severance costs. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $418 million and EPS of $0.54 for fiscal 2012.  Full Article

Symmetry Medical Inc. Reiterates FY 2012 Guidance
Thursday, 3 May 2012 07:02am EDT 

Symmetry Medical Inc. announced that for fiscal 2012, it expect revenue to be in the range of $410 million to $425 million, GAAP earnings per diluted (EPS) share to be in the range of $0.30 to $0.40 and adjusted earnings per diluted share to be in the range of $0.55 to $0.65. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $420 million for fiscal 2012.  Full Article

Symmetry Medical Inc Launches Enhancements To BOOKWALTER Surgical Retractor System
Friday, 23 Mar 2012 09:00am EDT 

Symmetry Medical Inc announced that it has launched twelve new line enhancements to the BOOKWALTER Retractor System through its hospital direct surgical instrumentation division, Symmetry Surgical. The new BOOKWALTER technology will be featured at the upcoming Annual Meeting of the Association of Operating Room Nurses (AORN), which will take place on March 26 to 29, 2012 in New Orleans. The BOOKWALTER Retractor System, was included as part of Symmetry's recent acquisition of the surgical instrument portfolio of Codman & Shurtleff.  Full Article

Symmetry Medical Inc. Reaffirms FY 2012 Revenue Guidance; Issues EPS Guidance In Line With Analysts' Estimates
Thursday, 23 Feb 2012 07:00am EST 

Symmetry Medical Inc. announced that for fiscal 2012, it continues to expect revenue to be in the range of $410 million to $425 million, GAAP earnings per diluted (EPS) share to be in the range of $0.30 to $0.40 and adjusted earnings per diluted share to be in the range of $0.55 to $0.65. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $422 million and EPS of $0.56 for fiscal 2012.  Full Article

Search Stocks